282 related articles for article (PubMed ID: 33131448)
1. Dermatological side effects of immunotherapy drugs and targeted cancer therapies: Importance of dermatology and oncology collaboration.
Çelik U; Aydemir EH; Engin B; Oba MÇ; Yılmaz M; Meşe ŞG
J Oncol Pharm Pract; 2021 Dec; 27(8):1853-1860. PubMed ID: 33131448
[TBL] [Abstract][Full Text] [Related]
2. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.
Lacouture M; Sibaud V
Am J Clin Dermatol; 2018 Nov; 19(Suppl 1):31-39. PubMed ID: 30374901
[TBL] [Abstract][Full Text] [Related]
3. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.
Grávalos C; Sanmartín O; Gúrpide A; España A; Majem M; Suh Oh HJ; Aragón I; Segura S; Beato C; Botella R
Clin Transl Oncol; 2019 May; 21(5):556-571. PubMed ID: 30284232
[TBL] [Abstract][Full Text] [Related]
4. Dermatological side effects of targeted antineoplastic therapies: a prospective study.
Agirgol S; Çaytemel C; Pilanci KN
Cutan Ocul Toxicol; 2020 Dec; 39(4):380-384. PubMed ID: 33028137
[TBL] [Abstract][Full Text] [Related]
5. Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study.
Barrios DM; Phillips GS; Freites-Martinez A; Hsu M; Ciccolini K; Skripnik Lucas A; Marchetti MA; Rossi AM; Lee EH; Deng L; Markova A; Myskowski PL; Lacouture ME
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1340-1347. PubMed ID: 31856311
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous Complications of Targeted Melanoma Therapy.
de Golian E; Kwong BY; Swetter SM; Pugliese SB
Curr Treat Options Oncol; 2016 Nov; 17(11):57. PubMed ID: 27645330
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
8. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
Yalici-Armagan B; Ayanoglu BT; Demirdag HG
Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
[No Abstract] [Full Text] [Related]
9. Skin rash associated with combined cytotoxic chemotherapy and immunotherapy for cancer: A retrospective single-center case series.
Yahiro C; Takai T; Nakatani S; Tanaka N; Goto A
J Dermatol; 2023 Mar; 50(3):357-363. PubMed ID: 36258256
[TBL] [Abstract][Full Text] [Related]
10. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
[TBL] [Abstract][Full Text] [Related]
11. Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer.
Tang N; Ratner D
Dermatol Surg; 2016 Jan; 42 Suppl 1():S40-8. PubMed ID: 26730973
[TBL] [Abstract][Full Text] [Related]
12. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic.
Rosen AC; Case EC; Dusza SW; Balagula Y; Gordon J; West DP; Lacouture ME
Am J Clin Dermatol; 2013 Aug; 14(4):327-33. PubMed ID: 23625802
[TBL] [Abstract][Full Text] [Related]
13. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
Plachouri KM; Vryzaki E; Georgiou S
Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies.
Plachouri KM; Florou V; Georgiou V; Georgiou S
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370736
[TBL] [Abstract][Full Text] [Related]
16. [Skin changes as a result of targeted therapies in oncology patients: cutaneous side effects of targeted therapies in oncology patients].
Kähler KC; Hauschild A
Hautarzt; 2009 May; 60(5):433-40. PubMed ID: 19430753
[TBL] [Abstract][Full Text] [Related]
17. Side effects of systemic oncological therapies in dermatology.
Zimmer L; Vaubel J; Livingstone E; Schadendorf D
J Dtsch Dermatol Ges; 2012 Jul; 10(7):475-86. PubMed ID: 22571234
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
[TBL] [Abstract][Full Text] [Related]
19. Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanoma.
Aguiar JP; Cardoso Borges F; Murteira R; Ramos C; Gouveia E; Passos MJ; Miranda A; da Costa FA
Int J Clin Pharm; 2018 Aug; 40(4):852-861. PubMed ID: 29860707
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]